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Abstract
Angiogenesis is a hallmark of cancer, promoting growth and
metastasis. Anti-angiogenic treatment has limited efficacy due to
therapy-induced blood vessel alterations, often followed by local
hypoxia, tumor adaptation, progression, and metastasis. It is there-
fore paramount to overcome therapy-induced resistance. We show
that Apelin inhibition potently remodels the tumor microenviron-
ment, reducing angiogenesis, and effectively blunting tumor
growth. Functionally, targeting Apelin improves vessel function
and reduces polymorphonuclear myeloid-derived suppressor cell
infiltration. Importantly, in mammary and lung cancer, Apelin
prevents resistance to anti-angiogenic receptor tyrosine kinase
(RTK) inhibitor therapy, reducing growth and angiogenesis in lung
and breast cancer models without increased hypoxia in the tumor
microenvironment. Apelin blockage also prevents RTK inhibitor-
induced metastases, and high Apelin levels correlate with poor
prognosis of anti-angiogenic therapy patients. These data identify
a druggable anti-angiogenic drug target that reduces tumor blood
vessel densities and normalizes the tumor vasculature to decrease
metastases.
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Introduction
Angiogenesis, the sprouting of new blood vessels from the existing
vasculature, is a hallmark of cancer that facilitates rapid tumor
growth and metastasis (Hanahan & Weinberg, 2011). Activation of
an “angiogenic switch” during cancer progression causes aberrant
capillary sprouting, tortuous and excessive vessel branching,
enlarged vessels, erratic blood flow, micro-hemorrhages, leakiness,
and abnormal endothelial cell proliferation (Hanahan & Weinberg,
2011). Inhibition of this angiogenic switch has therefore been
proposed as a key cancer treatment strategy. Given the importance
of vascular endothelial growth factors (VEGFs) in angiogenesis,
much attention has been focused on developing anti-angiogenic
receptor tyrosine kinase (RTK) inhibitors targeting the VEGFR
signaling pathway to treat a variety of cancers by blocking tumor
angiogenesis. Although various clinical trials have demonstrated the
efficacy of these therapies, the benefits are usually transitory and, in
certain cases, VEGFR pathway inhibitors may even lead to a more
aggressive disease (Carmeliet & Jain, 2011a).
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The large-scale eradication of tumor blood vessels results
in necrosis and hypoxia, which can trigger several resistance mecha-
nisms that drive tumor regrowth and malignancy (Bergers & Hana-
han, 2008; Carmeliet & Jain, 2011a; Potente et al, 2011). In recent
years, the concept of vessel normalization has been proposed to
restore vascular abnormalities in tumors, with vessels becoming less
permeable and better structured (Jain, 2001). Promoting vessel
normalization has been linked to decreased metastasis and an
increased efficacy of other therapies such as chemotherapies
(Carmeliet & Jain, 2011b; Leite de Oliveira et al, 2012; Maes et al,
2014). However, treatment with VEGF/VEGFR inhibitors alone leads
to a transient, usually rather short period of vessel normalization
after which hypoxia recurs and acquired resistance emerges (Rivera
& Bergers, 2015). In the last years, combination of VEGF and
angiopoietin-2 (Ang2) blockage has shown greater effects than
single targeting of both molecules in decreasing tumor growth,
angiogenesis, vascular abnormality, and metastasis (Brown et al,
2010; Koh et al, 2010; Kienast et al, 2013; Rigamonti et al, 2014;
Scholz et al, 2016; Allen et al, 2017; Schmittnaegel et al, 2017), thus
increasing the promise of anti-angiogenic VEGF-targeting in combi-
natory therapies. However, this strategy increased hypoxia (Koh
et al, 2010; Rigamonti et al, 2014; Scholz et al, 2016), which can
worsen the tumor microenvironment and induce treatment resis-
tance (Jain, 2014). Thus, there is a need to identify safe new agents
that can retain the therapeutic advantages of current anti-angiogenic
treatments, such as the reduction of angiogenesis and primary
tumor growth, and at the same time prevent its resistance-asso-
ciated features such as hypoxia and therapy-induced metastases.
Apelin is an evolutionarily conserved peptide that acts as the
endogenous ligand for the G protein-coupled Apelin receptor (Tate-
moto et al, 1998). The Apelin/Apelin receptor signaling pathway
has been implicated in developmental angiogenesis (Saint-Geniez
et al, 2002; Kasai et al, 2004, 2010; Cox et al, 2006; Ka¨lin et al,
2007; Kidoya et al, 2008; del Toro et al, 2010; Kidoya & Takakura,
2012). Although the Apelin/Apelin receptor pathway is downregu-
lated in adulthood, it is frequently reactivated and upregulated in
tumors (Sorli et al, 2007; Berta et al, 2010), including in endothelial
cells within the tumor microenvironment (Seaman et al, 2007).
Further, elevated levels of Apelin are associated with poor clinical
outcome in certain human cancers (Berta et al, 2010). Although
these observations make the Apelin/Apelin receptor pathway a
potentially attractive target for anti-angiogenic cancer therapy, the
detailed effects of its targeting for cancer treatment in vivo are poorly
understood. In addition, some reports suggest that the Apelin/Apelin
receptor pathway is not redundant with VEGFR signaling and that
both have independent roles in angiogenesis (Kidoya et al, 2008;
del Toro et al, 2010; Heo et al, 2012). Therefore, we wanted to
explore whether combinations of Apelin blockade with current
anti-angiogenic therapies may be of therapeutic benefit in cancer.
Here, we show that genetic and pharmacological inhibition of
Apelin is a feasible strategy to reduce tumor blood vessel formation,
vessel leakiness, and hypoxia, as well as to reduce suppressive
immune cell infiltration, thereby significantly diminishing growth of
primary lung and mammary tumors. In 3D vascular sprouts, Apelin
is essential for VEGF to trigger blood vessel outgrowth, indicating
that Apelin might be a key pathway that interfaces with VEGF
signaling. Combining targeting of Apelin with clinically relevant
RTK inhibitors like sunitinib, in vivo not only reduced blood vessel
density and leakage in tumors, but also decreased hypoxia and
metastases induced by sunitinib treatment. Further, elevated Apelin
levels in serum samples from renal cell cancer patients treated with
sunitinib as a single agent were associated with a worse prognosis.
Our findings unveil a new strategy that combines clinically relevant
anti-angiogenic treatments with Apelin inhibition to diminish tumor
growth, blood vessel density, and vessel abnormality within the
tumor environment, and thus hypoxia, tumor resistance, and anti-
angiogenic therapy-induced metastasis.
Results
Apelin blockage improves survival in mammary and lung
cancer models
To corroborate that Apelin expression is associated with outcome in
human breast cancer, we performed an unbiased meta-analysis of
multiple datasets using the Kmplot (Gyo¨rffy et al, 2010) and
PrognoScan (Mizuno et al, 2009) databases. We confirmed that high
levels of Apelin expression in tumors are significantly associated
with poor prognosis in breast cancer patients (Fig EV1A). Next, we
determined whether Apelin blockage is a suitable strategy to amelio-
rate cancer progression by ablating its expression in mammary
cancer. Apelin-deficient (Apln/) mice (Kuba et al, 2007) were
crossed with MMTV-NeuT transgenic mice (Lucchini et al, 1992) to
generate MMTV-NeuT; Apln/ and MMTV-NeuT; Apln+/+ control
littermates (termed NeuT;Apln/ and NeuT;Apln+/+ hereafter).
Apelin has been previously shown to be upregulated in tumor cells
(Seaman et al, 2007; Wang et al, 2007; Liu et al, 2015). We con-
firmed that Apelin expression is enhanced in tumors of MMTV-NeuT
mice compared to epithelial cells isolated from the mammary gland
of healthy mice (Fig EV1B), recapitulating human breast cancer
(Sorli et al, 2007) and validating our model. Importantly, NeuT;
Apln/ tumor-bearing mice displayed a delay in the onset of NeuT-
driven mammary tumors and a significantly prolonged survival
compared with NeuT;Apln+/+ littermates (Figs EV1C and 1A). In
line with enhanced survival, Apelin-null mice displayed a decreased
tumor burden in the mammary glands compared to age-matched
controls (Fig EV1D).
We further extended our studies to lung cancer as a second solid
tumor model of epithelial origin. Similar to breast cancer, we con-
firmed that high levels of Apelin expression are significantly associ-
ated with poor prognosis in lung cancer patients (Fig EV1E)
(Gyo¨rffy et al, 2013). To be able to experimentally dissect the role of
Apelin in lung cancer, Apln/ mice were crossed to the Lox-Stop-
Lox-KRasG12D lung cancer model (KRas;Apln+/y and KRas;Apln/y
hereafter; the Apelin gene is located on the X chromosome; Kuba
et al, 2007) (Jackson, 2001). We also extended the investigation to a
more aggressive form of non-small cell lung cancer (NSCLC) driven
by the KRasG12D oncogene combined with loss of the tumor suppres-
sor p53 (p53f/f;KRas;Apln+/y and p53f/f;KRas;Apln/y; DuPage et al,
2009). Knockout of Apelin resulted in enhanced survival and
reduced tumor burden in these lung cancer models (Fig EV1F–H).
We also explored whether Apela, the recently described second
ligand for Apelin receptor (Pauli et al, 2014), might also be overex-
pressed in NeuT-driven mammary tumors or KRas-driven lung
tumors, but we failed to detect its expression, even using sensitive
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and multi-cycle qPCR analysis. Thus, we conclude that Apelin is the
primary Apelin receptor ligand upregulated in our models of
mammary and lung cancer. Of note, we did not detect abnormalities
in mammary glands or lungs from non-tumor-bearing adult and
background-matched Apln+/+ and Apln/ mice without oncogenic
drivers. These results not only extend the findings of previous over-
expression studies (Sorli et al, 2007; Berta et al, 2010), but validate
Apelin as a target in tumor models of epithelial origin. Thus, high
Apelin levels correlate with a worse prognosis in breast and lung
cancer patients, and Apelin inactivation increases the survival of
mice with breast and lung cancer.
Apelin modulates the tumor microenvironment through
paracrine stimulation of tumor angiogenesis
Apelin has previously been shown to stimulate tumor angiogenesis
and is upregulated in tumor-associated endothelial cells (Seaman
et al, 2007; Wang et al, 2007; Liu et al, 2015), which we could con-
firm in endothelial cells isolated from MMTV-NeuT tumors
compared to normal mammary gland (Fig EV2A). Despite the
known role of Apelin in tumor angiogenesis, the detailed effects of
Apelin within the tumor cells and its microenvironment in vivo
remain poorly understood.
To study the contribution to tumor growth of Apelin from cancer
cells or cells of the tumor microenvironment, we used the E0771
mammary cancer model and, first, specifically downregulated the
expression of Apln in cancer cells using shRNA (Fig EV2B). Then,
we orthotopically injected control shRenilla E0771 cells and Apln-
depleted (shApln) E0771 cells into syngeneic C57BL/6J Apln+/+ as
well as Apln/ mice (Fig 1B). Comparing Apelin wild-type
(Apln+/+;E0771 shRen) with Apelin-depleted (Apln/;E0771
shApln) tumors, we could recapitulate the phenotype observed with
the constitutive Apelin knockout in the NeuT model (Fig 1A and B).
By specifically depleting Apelin expression in tumor epithelial cells
(Apln+/+;E0771 shApln) or the cells of the tumor microenviron-
ment (Apln/;E0771 shRen), we could investigate the importance
of these two sources of Apelin for the observed growth decrease in
fully Apelin-depleted tumors (Apln/;E0771 shApln). We found
that both Apelin sources are of equal importance for the Apelin-
mediated increase in tumor growth (Fig 1B).
While the Apelin receptor has been detected in both tumor and
endothelial cells, we find that its expression was considerably
higher in tumor-associated endothelial cells (Fig EV2C). To assess
whether Apelin exerts its effects in the tumor epithelial cells or in
the tumor endothelial cells, we used the E0771 mammary cancer
model and specifically downregulated the expression of the Apelin
receptor (Aplnr) in the cancer cells using shRNA (Fig EV2B).
Whereas in vitro shRenilla, shApln and shAplnr E0771 cells grew
similarly (Fig EV2D), tumors from injected shAplnr E0771 cells in
syngeneic wild-type mice did not show a reduction in tumor
growth compared to tumors from injected shRenilla E0771 cells, in
contrast to tumors from shApln E0771 cells (Fig EV2E). In addi-
tion, only tumors from shApln E0771 cells presented a decreased
microvessel density (Fig EV2F), indicating that tumor epithelial
cell-derived Apelin induces tumor angiogenesis in a paracrine
fashion.
Importantly, loss of Apelin expression also significantly
decreased microvessel densities in both E0771 and NeuT-driven
mammary tumors, as well as KRasG12D-driven lung tumors (Fig 1C,
and Appendix Fig S1A and B). Functionally, E0771 shApln cells
injected into Apln/ mice displayed markedly reduced vessel leak-
age in vivo as compared to control shRenilla E0771 cells injected
into Apln+/+ mice (Fig 1D). Using pimonidazole staining to detect
tissue hypoxia (Varia et al, 1998) revealed a decreased number of
hypoxic foci in shApln E0771 mammary tumors (Fig 1E).
Angiogenic proteins, like VEGF, have been reported to be able to
affect immune cell infiltration in different tumor models (Yang et al,
2018). To complement our findings, we profiled the immune cell
infiltration in the Apln+/+;E0771 shRenilla and Apln/;E0771
shApln tumor groups. While total immune cell infiltration, as deter-
mined by the numbers of CD45+ cells in the tumor, was unchanged
(Appendix Fig S1C), we found a significant decrease of polymor-
phonuclear myeloid-derived suppressor cells (PMN-MDSC) and a
significant increase in NK T cells in tumor from Apelin-depleted
mice (Fig 1F). Of note, it has been previously reported that PMN-
MDSC cells accumulate in hypoxic tumor regions and are associated
◀ Figure 1. Genetic and pharmacological inhibition of Apelin impairs mammary tumor growth and tumor angiogenesis in a paracrine manner.A Kaplan–Meier plot for survival in NeuT;Apln+/+ (n = 11) and NeuT;Apln/ (n = 10) mice with mammary cancer after tumor onset. *P = 0.0185; log-rank test. Mice
were sacrificed when the tumor size reached 1 cm3, following ethical guidelines.
B Tumor volumes, followed over time, of control mammary tumor E0771 cells (shRenilla) and Apelin-depleted (shApln) E0771 cells orthotopically injected into both
syngeneic C57BL/6J Apln+/+ and Apln/ mice (5 × 105 cells/mouse), respectively. Tumor volumes were determined using calipers and are shown as mean tumor
volumes  SEM. Data shown are pooled from two independent experiments. Apln+/+;shRenilla (n = 18), Apln+/+;shApln (n = 17), Apln/;shRenilla (n = 14), Apln/;
shApln (n = 15); **P < 0.01, ***P < 0.001; two-way ANOVA.
C Mean percentages (SEM) of CD31+ area in E0771 shRenilla (n = 3) or shApln (n = 3) mammary tumors, assessed on day 23 post-orthotopic injection into C57BL/6J
Apln+/+ or Apln/ mice, respectively. **P < 0.01; t-test.
D Mean percentages (SEM) of extravasated Dextran in E0771 shRenilla (n = 9) or shApln (n = 12) mammary tumors, assessed on day 19 post-orthotopic injection into
C57BL/6J Apln+/+ or Apln/ mice, respectively. **P < 0.01; t-test. Right panel shows representative immunofluorescence of Dextran (red), CD31+ vessels (green), and
DAPI (blue). The white arrows indicate regions of Dextran extravasation. Scale bars = 100 lm.
E Mean counts (SEM) of pimonidazole positive foci, assessed on day 26 post-orthotopic injection of E0771 shRenilla (n = 6) or shApln (n = 4) into C57BL/6J wild-type
mice (5 × 105 cells/mouse). *P < 0.05; t-test. Right panels show representative immunohistochemical pimonidazole staining at two different magnifications; scale
bars = 200 lm (upper panels) and 50 lm (lower panels).
F Mean percentage (SEM) of tumor-infiltrating immune cells normalized to CD45+. E0771 shRenilla (n = 8) or shApln (n = 6) were orthotopically injected into C57BL/6J
Apln+/+ or Apln/ mice (5 × 105 cells/mouse), respectively, and tumors were harvested day 25 post-injection. *P < 0.05, **P < 0.01; t-test. All immune cell populations
were gated for viable CD45+ cells and then further defined as: CD8 T cells (Thy1.2+, CD8+), CD4 T cells (Thy1.2+, CD4+), inflammatory monocytes (Ly6C+, Cd11b+,
Ly6G), PMN-MDSCs (Ly6G+, Cd11b+), natural killer cells (Thy1.2, Ly6G, NK1.1+), natural killer T cells (Thy1.2+, CD4, CD8, NK1.1+), and peripheral dendritic cells
(Ly6G,Ly6C+, Cd11b, PDAC1+, B220+).
Source data are available online for this figure.
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with increased angiogenesis in vivo and enhanced tumor cell inva-
sion (Marvel & Gabrilovich, 2015). Together, these results show that
tumor cell-derived as well as microenvironment-derived Apelin
contributes to cancer progression through stimulation of tumor
angiogenesis, enhancing vessel leakiness and tumor hypoxia, and
altered infiltration of immune cells.
Apelin induces pro-angiogenic pathways in endothelial cells and
enhances VEGF-induced vessel sprouting
Having established that Apelin is a modulator of tumor blood
vessels, we next explored gene expression changes of CD31+/
CD105+ endothelial cells (ECs) sorted from Apelin wild-type and
Apln-depleted tumors. We used ingenuity pathway analysis (IPA) to
predict regulation of downstream biological processes and found a
significant decrease in processes associated with endothelial cell
proliferation and angiogenesis in ECs sorted out of Apelin-depleted
tumors (Fig 2A), consistent with our previous findings (Fig 1C,
Appendix Fig S1A and B). Further, IPA predicted a decrease in the
adhesion of granulocytes (the cellular family to which PMN-MDSCs
belong), also in line with our findings (Figs 1F and 2A). IPA is also
suitable to predict upstream regulators and their activation state
based on the up- or downregulation of differentially expressed
genes. We find that proteins of the TGF superfamily, Inhibin-bA and
TGF-b1, as well as C/EBP-a, b-catenin, ErbB2 and EGFR are
predicted to be inhibited upstream regulators in ECs isolated from
Apelin-depleted tumors (Fig EV3A). Thus, Apelin depletion results
in impaired angiogenesis as determined by decreased blood vessel
numbers and transcriptome analysis of tumor-associated endothelial
cells.
To further investigate the role of Apelin in angiogenesis, we used
an in vitro system of 3D vessel sprouting from embryoid bodies
(EBs) that allowed us to study active angiogenesis in a controlled
environment, mimicking in vivo vessel growth (Jakobsson et al,
2010). Although Apelin stimulation alone was not sufficient to initi-
ate vessel sprouting, we found that it strongly increased VEGF-
dependent vessel growth (Fig EV3B). We next generated Apelin
mutant mouse embryonic stem cells (mESCs) using a gene-trap
strategy in haploid stem cells (Elling et al, 2011, 2017). A sense
splice acceptor disrupted Apelin mRNA expression (Apln STOP
mESCs), whereas Cre expression “genetically repaired” Apelin
expression in sister cells (Apln GO mESCs; Fig EV3C and D).
Although Apln STOP mESCs displayed comparable growth kinetics
(Fig EV3E), Apln STOP EBs exhibited markedly delayed sprouting
upon VEGF treatment compared with their Apln GO controls
(Fig 2B). Of note, Cre expression per se did not affect vessel sprout-
ing compared to a non-Cre control. Thus, Apelin enhances VEGF-
induced vessel sprouting in vitro.
To characterize the functional behavior of endothelial cells with
or without Apelin, we performed competition assays in which
chimeric EBs were established by mixing Apln GO: Apln STOP sister
mESCs 1:1 followed by stimulation with VEGF. To track Apln GO
and Apln STOP cells, we incorporated a GFP signal in our gene-trap
strategy and a mCherry signal in our retroviral Cre vector; Apln
STOP targeted cells are GFP+ and Apln GO cells are mCherry+
(Fig EV3C). Chimeric EBs treated with VEGF showed a significant
decrease in the ratio of Apln STOP (GFP+):Apln GO (mCher-
ry+Cre+) endothelial cells by FACS analysis (Fig EV3F), confirming
the functional disadvantage of Apelin STOP cells in vessel
sprouting.
In line with in vivo EC RNA sequencing (RNA-Seq) and delayed
vessel sprouting, downregulated genes of purified CD31+ ECs
isolated from sprouting Apln STOP EBs treated with VEGF showed
angiogenesis as the top affected gene ontology category compared
with Apln GO control cells (Fig 2C). In addition, loss of Apelin
modulated pathways in endothelial cells related to vasculogenesis,
cell adhesion, and response to hypoxia (Fig 2C). IPA identified
VEGF as the main upstream regulator predicted to be inhibited in
Apelin-depleted endothelial cells, closely followed by TGFb1 and
TNF, all reduced in the absence of Apelin (Fig EV3G). Indeed, genes
that IPA predicted to be downstream of VEGF showed strong down-
regulation in Apelin-depleted ECs and were enriched for angiogene-
sis-related genes (Fig EV3H). Thus, in a controlled model of VEGF-
induced angiogenesis, Apelin and VEGF induce similar downstream
pathways and genes relevant for endothelial cell proliferation and
blood vessel sprouting, suggesting that Apelin inhibition could
complement and potentiate current anti-angiogenic cancer treat-
ment.
Apelin ablation enhances effectiveness of
anti-angiogenic treatment
Since we observed that Apelin depletion decreased VEGF-dependent
vessel sprouting (Figs EV3C–H, and 2B and C), we aimed to study
the effects of targeting Apelin in tumors in combination with clini-
cally used anti-angiogenic treatments using inhibitors targeting
receptor tyrosine kinases (RTKIs). We selected sunitinib, an inhi-
bitor of multiple receptor tyrosine kinases implicated in angiogene-
sis, including VEGFR1, VEGFR2, and VEGFR3, PDGFRa, PDGFRb,
Kit, and others (Kim et al, 2014). Further, sunitinib is approved for
clinical use in renal cell carcinoma, gastrointestinal stromal tumor
and pancreatic neuroendocrine tumors (Rock et al, 2007; de Wilde
et al, 2012).
To determine if blocking the Apelin pathway could complement
current anti-angiogenic therapies, we administered sunitinib to
NeuT;Apln/ and NeuT;Apln+/+ mice at the time of mammary
tumor onset. In NeuT+ mice, Apelin ablation combined with suni-
tinib treatment significantly increased survival and reduced the
tumor burden compared with either intervention alone (Fig 3A and
B); blocking Apelin almost doubled the survival of sunitinib-treated
mice and tripled the survival compared to control untreated mice
(Fig 3A). It should be noted that mice had to be sacrificed when
reaching a particular tumor size following ethical guidelines. Similar
results were observed with E0771 mammary cancer cells (Fig EV4A)
and with axitinib, a second clinically used anti-angiogenic treatment
(Fig EV4B), extending our findings to several cancer models and
drugs. To further test whether Apelin cooperates with VEGFR signal-
ing and whether the combinational blockage of both could be
exploited in anti-cancer treatment, we treated shRenilla and shApln
E0771 cell-bearing C57BL/6J mice with a specific anti-VEGFR2 anti-
body (DC101 clone) and obtained similar results as with sunitinib
and axitinib treatments (Fig EV4C). These data show that combin-
ing Apelin inhibition with other inhibitors of angiogenesis markedly
delays mammary cancer growth.
We next followed individual tumors in vivo using non-invasive
magnetic resonance imaging (MRI). MRI analysis of tumor volume
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confirmed that inactivation of Apelin decreased the growth rate of
NeuT+ mammary tumors to levels comparable to sunitinib treat-
ment (Fig 3C and Movie EV1). Importantly, sunitinib-treated NeuT;
Apln/ tumors showed a significant decrease in tumor growth
(Fig 3C and Movie EV1), as well as reduced mitotic counts and Ki67
staining (Figs 3D and EV4D). Decreased mitotic counts and Ki67
levels are established markers of better prognosis in breast cancer
(van Diest et al, 2004). Finally, we used MM54, an Apelin antago-
nist with a KD of 3.4 lM and no reported agonistic activity, to block
Apelin signaling (Macaluso et al, 2011; Harford-Wright et al, 2017).
Pharmacologic inhibition of Apelin signaling by MM54 had the same
effect as genetically ablating Apelin expression, synergizing with
sunitinib to reduce tumor progression (Fig 3E). We obtained similar
results on overall survival, tumor growth, and tumor cell prolifera-
tion in the p53f/f;KRas lung cancer model (Appendix Fig S2A–C).
These data in mammary cancer and KRas-driven lung cancer models
indicate that inhibition of Apelin signaling improves the efficacy of
anti-angiogenic therapy to impair primary tumor growth and
promote survival.
Combined Apelin and VEGFR inhibition normalizes blood vessels
and prevents hypoxia in tumors
Previous findings have shown that RTKIs, despite reducing tumor
vasculature and growth, have no or limited beneficial effects in
cancer treatment. As one explanation, it has been reported that anti-
VEGFR treatment results in local hypoxia and consequently more
metastases (Bergers & Hanahan, 2008). Therefore, we examined the
tumor microenvironment and tumor cell dissemination. Having
shown that inhibition of Apelin and administration of sunitinib
markedly improves the outcome in different cancer models, we first
assessed the impact of this combination therapy on the tumor
vasculature. Size-matched early stage tumors were imaged by 15.2
Tesla MRI at 2, 4, and 6 weeks, and the relative tumor blood
volume (rTBV) was assessed (Fig 4A). Whereas control NeuT;
Apln+/+ tumors showed an increase in rTBV over time, sunitinib
treatment reduced the rTBV in the tumors (Fig 4B and C), con-
firming previous data (Pa`ez-Ribes et al, 2009). NeuT;Apln/
tumors also displayed reduced rTBV, though to a lesser extent.
Notably, sunitinib treatment of NeuT;Apln/ tumors enhanced the
decrease in rTBV compared to either condition alone, and this was
maintained over the entire observation period (Fig 4B and C). We
corroborated the rTBV MRI analysis with anti-CD31 immunostaining
to determine blood vessel density within tumors (Fig 4D and E). In
contrast to sunitinib-treated NeuT;Apln+/+ tumors that displayed
low vessel density and poor vessel structure, characterized by
dilated blood vessels and reduced mural cell coverage, as deter-
mined by the ratio of aSMA+-positive vascular smooth muscle cells
to CD31+ endothelial cells, sunitinib-treated NeuT;Apln/ tumors
exhibited markedly lower vessel densities and, importantly, normal-
ized blood vessel structures (Fig 4D and E).
Next, we examined the functional consequences of combined
Apelin inactivation and anti-angiogenic therapy on local hypoxia
and leakage of the tumor vasculature. Sunitinib treatment of NeuT;
Apln+/+ tumors increased the percentage of hypoxic cells adjacent
to tumor blood vessels compared to untreated NeuT;Apln+/+
tumors, evaluated by prototypic carbonic anhydrase 9 (CA9)
immunostaining (Fig 5A; Olive et al, 2001). In contrast, loss of
Apelin reduced the percentage of hypoxic cells adjacent to tumor
blood vessels in untreated and, most substantially, in sunitinib-
treated NeuT;Apln/ tumors (Fig 5A). To complement these stud-
ies, we used MRI to visualize the dynamics of vessel permeability
over time upon sunitinib therapy and Apelin targeting, following the
same scheme used for rTBV assessment (see Fig 4A). Systematic
dynamic susceptibility contrast (DSC) perfusion analysis in tumor
tissue by MRI confirmed that sunitinib-treated NeuT;Apln/
tumors have the lowest vessel permeability (Fig 5B and C).
Together, our data reveal that combined inhibition of angiogenic
pathways not only reduces tumor growth and angiogenesis but also
improves blood vessel structure relative to either condition alone.
Importantly, loss of Apelin prevents the detrimental effects of
sunitinib treatment on blood vessel structure, leakage, and local
hypoxia.
Apelin loss prevents sunitinib-induced metastases
Tumors treated with sunitinib display increased hypoxia and inva-
siveness upon therapy-induced resistance, resulting in more metas-
tasis, which cannot be reverted by stopping the treatment (Ebos
et al, 2009; Pa`ez-Ribes et al, 2009). Therefore, we next evaluated
how sunitinib treatment and loss of Apelin signaling affect the
metastatic status of NeuT;Apln+/+ and NeuT;Apln/ mice. We
analyzed lungs of tumor-bearing mice 6 weeks after the primary
mammary tumors were size-matched at 20–70 mm3 (see Fig 6A).
Although untreated NeuT;Apln+/+ mammary tumors are not highly
metastatic, sunitinib treatment significantly increased the number of
◀ Figure 2. Apelin deletion delays VEGF-induced blood vessel sprouting.A Left—Heatmap of RNA-Seq transcriptome analysis of CD31+/CD105+ endothelial cells sorted from tumors established by E0771 shRenilla (n = 6) or shApln (n = 3) cells
orthotopically injected into C57BL/6J Apln+/+ or Apln/ mice, respectively. Tumors were harvested day 25 post-injection and genes displayed are significantly
deregulated at the adjusted P-value cutoff of 0.05. Right—ingenuity pathway analysis for biological processes predicted to be decreased downstream of the
differentially expressed genes.
B Quantification of vessel sprouts (mean values  SEM) upon VEGF treatment (30 ng/ml) of embryoid bodies (EB) derived from murine ES cells (mESCs) with sense
integrations in the Apelin gene (Apln STOP) of the splice acceptor described in Appendix Fig S1B or Cre-reverted antisense (Apln GO) sister cells. Apln GO (Day 2 n = 6;
Day 4 n = 40, Day 6 n = 54, Day 8 n = 32, Day 10 n = 35, Day 11 n = 31), Apln STOP (Day 2 n = 4; Day 4 n = 15, Day 6 n = 31, Day 8 n = 28, Day 10 n = 32, Day 11
n = 37); **P < 0.01, ***P < 0.001, two-way ANOVA. Representative brightfield images and automated analysis of vessel sprouts by Definiens software are shown in
the bottom panels. Scale bars = 200 lm.
C Differentially expressed genes using RNA-Seq transcriptome analysis of CD31+ endothelial cells (ECs) sorted from sprouting EBs from Apelin STOP cells stimulated
with VEGF (30 ng/ml) and DMSO (Apln) and repaired Apelin GO sister cells stimulated with VEGF and Apelin (1,000 nM; +Apln). VEGF target genes and angiogenesis-
related genes, predicted by ingenuity pathway analysis (IPA) software, are indicated by bars on the upper axis of the heatmap. GO terms were analyzed by DAVID
online software.
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lung metastases (Fig 6A), as previously observed (Ebos et al, 2009;
Pa`ez-Ribes et al, 2009). Apelin inactivation alone did not signifi-
cantly alter metastasis of NeuT-driven tumors. However, deletion of
Apelin prevented sunitinib-induced lung metastases (Fig 6A). We
obtained similar results in NeuT+ mice with large size-matched
mammary tumors (Fig EV5A). Further, we found that sunitinib
treatment induced metastasis of tumors derived from shRenilla
E0771 cells but not from shApln E0771 cells, providing additional
evidence that Apelin inhibition prevents sunitinib-induced metasta-
sis (Fig EV5B and C).
To complement our studies in mice, we investigated whether
Apelin levels correlate with the metastatic status of women with
breast cancer. Unbiased meta-analysis using the Kmplot database
(Gy}orffy et al, 2010) indeed showed that high levels of intra-
tumoral Apelin expression significantly associated with an acceler-
ated appearance of distant metastases in breast cancer (Fig 6B).
These results suggest that Apelin levels are a potential prognostic
biomarker for metastasis, with higher levels correlating with a
shorter time to metastasis in breast cancer patients. Our experi-
mental mouse results show that, unlike sunitinib treatment, loss
of Apelin does not increase metastasis. Rather, Apelin inhibition
not only reduces tumor growth in our mammary tumor models,
but also reduces the occurrence of anti-angiogenic therapy-
induced metastases.
High Apelin levels correlate with poor prognosis of patients on
sunitinib therapy
Sunitinib is a first-line therapy for renal cell carcinoma (RCC) as a
single agent (Kim et al, 2014). However, even in the treatment of
RCC patients, it only temporarily stabilizes the disease (Kim et al,
2014). Based on our results, we hypothesized that low Apelin levels
may correlate with a better prognosis in patients treated with anti-
angiogenic therapy. To test this hypothesis, we measured Apelin
levels in serum samples from a cohort of 55 RCC patients that were
treated for 3–5 months with sunitinib as a single agent
(Appendix Fig S3A) and evaluated their progression-free survival
(PFS). RCC patients with lower Apelin levels indeed had a signifi-
cantly longer PFS (median survival = 459.5 days) than patients with
higher Apelin levels (median survival = 280 days; Fig 6C and
Appendix Fig S3B). We also evaluated the serum levels of both
VEGF and Apelin in our cohort of sunitinib-treated RCC patients and
stratified high or low expression groups based on the median
(Fig 6D). Patients with both low Apelin and low VEGF serum levels
had a significantly higher PFS (median survival = 623 days),
whereas patients with high serum levels of both proteins had the
lowest median survival (167 days). Low levels of only Apelin or
VEGF showed a median survival of 340.5 and 343 days, respectively
(Fig 6D). Taken together, these results indicate that high Apelin
levels in serum samples correlate with worse prognosis of renal
cancer patients treated with approved and clinically utilized anti-
angiogenic therapy.
Discussion
Tumor angiogenesis is required to nourish rapidly growing trans-
formed cells. Anti-angiogenic therapies currently in clinical use are
based on the inhibition of VEGF and closely related pathways (Cao
et al, 2011; Jayson et al, 2016). However, in many cases, anti-angio-
genic therapies result in abnormal blood vessels and local hypoxia
in tumors, leading to even more aggressive growth and conse-
quently metastases, thereby limiting the promise of blood vessel
targeted anti-cancer approaches (Bergers & Hanahan, 2008; Carme-
liet & Jain, 2011a; Potente et al, 2011; Rivera & Bergers, 2015).
Emerging evidence shows that combinational therapies have usually
higher effectiveness than monotherapies for cancer treatment. Based
on this concept, we aimed to identify novel druggable pathways that
can alleviate the detrimental effects of current anti-angiogenic thera-
pies while maintaining their efficacy. Here, we show that ablating
the small peptide Apelin strikes one Achilles heel of current anti-
angiogenic therapy, reducing tumor angiogenesis and growth of the
primary tumor while at the same time maintaining a better struc-
tured vasculature with higher pericyte coverage, impairing malig-
nant progression, preventing hypoxia and distant metastasis.
One intriguing aspect of our findings is that inactivation of
Apelin not only reduces tumor growth and cancer neo-angiogenesis
in combination with anti-angiogenic therapy, but results in tumor
◀ Figure 3. Combining Apelin blockage and anti-angiogenic treatment improves survival and reduces mammary tumor growth.A Experimental setup and (right) Kaplan–Meier survival plot of NeuT;Apln+/+ and NeuT;Apln/ mice with mammary cancer, left untreated (control) or treated with the
indicate dose of the broad VEGFR blocker sunitinib. NeuT;Apln+/+ control (n = 8), NeuT;Apln/ control (n = 11), NeuT;Apln+/+ sunitinib (n = 11), NeuT;Apln/ sunitinib
(n = 12); *P < 0.05; ***P < 0.001; log-rank test. Mice were sacrificed when the tumor size reached 1 cm3, following ethical guidelines. The dotted line indicates 50%
of survival.
B Percentages (mean  SEM) of tumor burden in mammary glands of untreated (control) and sunitinib-treated NeuT;Apln+/+ and NeuT;Apln/ mice, assessed 4 weeks
after tumor onset. NeuT;Apln+/+ control (n = 6), NeuT;Apln/ control (n = 8), NeuT;Apln+/+ sunitinib (n = 5), NeuT;Apln/ sunitinib (n = 5); *P < 0.05; ***P < 0.001;
one-way ANOVA. Representative H&E images are shown for each genotype in the right panels. Scale bars = 1,000 lm (large panels) and 50 lm (insets).
C Tumor volumes of untreated (control) and sunitinib-treated NeuT;Apln+/+ and NeuT;Apln/ mammary tumors, size-matched at 20–70 mm3 and followed over time by
MRI analysis; NeuT;Apln+/+ control (n = 7), NeuT;Apln/ control (n = 5), NeuT;Apln+/+ sunitinib (n = 5), NeuT;Apln/ sunitinib (n = 6) mice per group; lines represent
nonlinear fit of tumor growth. Box and arrow indicate the time point used for analysis in panel (D).
D Mitotic counts (mean  SEM) and representative H&E images of mammary tumors in untreated (control) and sunitinib-treated NeuT;Apln+/+ and NeuT;Apln/ mice,
assessed 6 weeks after tumor onset.; NeuT;Apln+/+ control (n = 7), NeuT;Apln/ control (n = 6), NeuT;Apln+/+ sunitinib (n = 9), NeuT;Apln/ sunitinib (n = 4) tumors
per group; *P < 0.05; one-way ANOVA to sunitinib-treated NeuT;Apln/. White arrows indicate mitotic figures. Scale bars = 50 lm.
E Tumor volumes, followed over the indicated time, of orthotopically injected E0771 shRenilla cells left untreated (control) or treated three times a week from day 8
after tumor injection with an Apelin antagonist alone (MM54, 0.4 lg/g), sunitinib alone (60 mg/kg) or a combination of both. Tumor volumes were measured using
calipers and are shown as mean tumor volumes  SEM. E0771 shRenilla control (n = 6), MM54 (n = 5), sunitinib (n = 5), sunitinib + MM54 (n = 5); *P < 0.05,
**P < 0.01, ***P < 0.001, two-way ANOVA.
Source data are available online for this figure.
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blood vessel normalization as defined by less capillary leakage,
reduced tissue hypoxia, and maintained pericyte coverage. While
sunitinib has been tested in many clinical trials for its capability to
reduce tumor growth, due to limitations in trial design and patient
recruitment, a conclusive analysis whether sunitinib is increasing
metastasis in human disease is still outstanding. As reported previ-
ously, sunitinib robustly induces metastases in mouse models (Ebos
et al, 2009; Pa`ez-Ribes et al, 2009; Singh et al, 2012). Intriguingly,
we did not observe an increase in metastasis upon Apelin blockage
alone in both of our mammary cancer models. Importantly, Apelin
blockade not only normalized blood vessels within the tumors but
prevented the enhanced hypoxia and consequent metastases in
animals treated with sunitinib. Thus, inhibition of distinct inducers
of angiogenesis from different receptor families provides an addi-
tional benefit in lung and mammary cancer models.
Our experimental models using E0771 mammary tumor cells,
NeuT oncogene-driven spontaneous mammary cancer, as well as
clonal induction of oncogenic KRas to trigger lung cancer, clearly
demonstrate that loss of Apelin alone markedly reduces tumor
angiogenesis, impairs tumor growth, and as a consequence
improves survival of these animals. We find that impairing Apelin
expression from both, the epithelial tumor cells, as well as from
cells in the tumor microenvironment, is key to reduce tumor
growth. We further show that Apelin depletion remodels the tumor
microenvironment, by improving vessel leakiness, reducing hypox-




Figure 4. Combining Apelin blockage and sunitinib treatment reduces tumor angiogenesis and normalizes tumor blood vessels.
A Experimental setup for the MRI (non-invasive magnetic resonance imaging) experiments.
B, C (B) Representative MRI images; scale bar = 5 mm and (C) quantification (mean  SEM) of relative tumor blood volume (rTBV) over time after NeuT+ mammary
tumors were size-matched at 20–70 mm3 (0 weeks). Treatments and genotypes are indicated. NeuT;Apln+/+ control (n = 4), NeuT;Apln/ control (n = 4), NeuT;
Apln+/+ sunitinib (n = 5), NeuT;Apln/ sunitinib (n = 5); **P < 0.01, and ***P < 0.001 compared to untreated NeuT;Apln+/+ mice and #P < 0.05 compared to
untreated control NeuT;Apln/ mice; two-way ANOVA. Of note, in NeuT;Apln+/+ mice, only two tumors could be analyzed after 6 weeks as some mice had to be
sacrificed due to the large tumor sizes following ethical guidelines. Thus, we did not perform any statistical analysis on the 6 weeks time points.
D Analysis (mean values  SEM) of CD31+ area (×104 lm2)/field, number of dilated tumor vessels, and percentage of alphaSMA+ area per CD31+ blood vessels in
mammary tumors of untreated (control) and sunitinib-treated NeuT;Apln+/+ and NeuT;Apln/ mice, assessed 6 weeks after mammary tumors were size-matched.
NeuT;Apln+/+ control (n = 4), NeuT;Apln/ control (n = 4), NeuT;Apln+/+ sunitinib (n = 5), NeuT;Apln/ sunitinib (n = 4); *P < 0.05; **P < 0.01; ***P < 0.001; one-
way ANOVA and Kruskal–Wallis test.
E Representative immunofluorescence and immunohistochemistry images from Fig 5D quantification. Dilated blood vessels are marked by a red asterisk. DAPI (blue)
is shown as a counterstain to visualize nuclei. Scale bars = 100 lm (upper panels), 50 lm (middle panels), and 20 lm (lower panels).
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T cells. PMN-MDSCs are an immune-suppressive subset of the
neutrophil lineage that suppress immune responses in an antigen-
dependent manner (Gabrilovich, 2017). MDSCs in general, can be
recruited into hypoxic tissues and PMN-MDSCs in particular have
been shown to be capable of promoting angiogenesis (Binsfeld et al,
2016). Importantly, MDSCs are implicated in mediating resistance to
anti-angiogenic therapy by promoting new vessel growth and PMN-
MDSCs numbers have been correlated with responsiveness to suni-
tinib therapy (Condamine et al, 2015). Our gene expression profiles
further indicate that Apelin-depleted endothelial cells express factors
involved in the recruitment of PMN-MDSCs. Whether the loss of
Apelin affects the homing and/or local expansion of PMN-MDSCs
needs to be examined in future experiments.
The effects of Apelin depletion on tumor cells and the cells of the
tumor microenvironment might be model and context dependent. A
recent publication found that Apelin depletion presents a double-
edged sword in glioblastoma, since it enhanced tumor cell invasion,
while at the same time reducing vascular density, without accompa-
nied changes in immune cell infiltration (Mastrella et al, 2019). In
contrast to this study in glioblastoma, we find a consistent benefit of
depleting Apelin in epithelial breast and lung cancer, associated
with normalized vessel function, decreased hypoxia, and conse-
quently reduced metastases. Importantly, in this glioblastoma study,
it was also reported that a combination of Apelin-F13A with anti-
VEGFR2 therapy is superior to either intervention alone. Apelin-
F13A is a poorly understood molecule proposed to be an antagonist
of Apelin signaling but was shown to also exert agonistic effects
(Fan et al, 2003; Medhurst et al, 2003; Lee et al, 2005). The combi-
nation of anti-angiogenic treatment with Apelin-F13A seems to be
promising in glioblastoma, but due to its unclear mechanism of
action its wider applicability as potential therapeutic in other types
of cancers remains questionable. Nonetheless, it appears that Apelin
is an ubiquitously used angiogenic pathway throughout many dif-
ferent types of cancers, i.e., glioblastoma, lung, and breast cancer.
Whether Apelin exerts similar effects in other tumor types requires
further studies.
One of the key factors limiting clinical benefits of anti-angiogenic
therapy in cancer patients is to define reliable biomarkers discrimi-
nating responsive patients from non-responders. At the time of writ-
ing, to our knowledge such a reliable biomarker does not exist for
guiding clinical practice. In multiple cancers, including breast and
lung, Apelin expression levels in tumors inversely correlate with
overall survival as well as metastasis-free survival (our data and
Berta et al, 2010; Heo et al, 2012). To directly correlate Apelin
expression with anti-angiogenic benefits, we accessed a cohort of
renal cell carcinoma patients who received anti-angiogenic sunitinib
monotherapy. High circulating Apelin levels in patients receiving
anti-angiogenic therapy correlated with worse survival. Our data
also show that serum Apelin levels in patients treated with sunitinib
represent a potential biomarker to predict the efficacy of anti-
vascular drugs and to identify patients responsive to these therapies.
This is in line with recent data in 30 patients with colorectal cancer,
suggesting that Apelin expression may represent a predictive
biomarker for bevacizumab unresponsiveness (Zuurbier et al,
2017), independently confirming our results in human patients.
Normalization of blood vessels has become a critical concept to
fully realize the clinical benefits of anti-angiogenic therapy.
Although a combination therapy blocking both VEGF and
A B C
Figure 5. Apelin inactivation reduces sunitinib therapy-induced hypoxia and vessel permeability.
A Percentages of CA9+ cells adjacent to CD31+ tumor blood vessels (mean  SEM) in untreated (control) and sunitinib-treated NeuT;Apln+/+ and NeuT;Apln/ mice,
6 weeks after mammary tumors were size-matched. NeuT;Apln+/+ control (n = 4), NeuT;Apln/ control (n = 4), NeuT;Apln+/+ sunitinib (n = 4), NeuT;Apln/
sunitinib (n = 4); 100–200 peri-vascular intra-tumoral regions per group were counted. ***P < 0.001; one-way ANOVA. Right panels show representative
immunofluorescent images. Areas limited by dotted white lines indicate CA9+ areas. Scale bars = 50 lm.
B, C (B) Representative MRI images; scale bar = 5 mm and (C) quantification (mean  SEM) of vessel permeability (K2) in NeuT+ mammary tumors followed over time.
Treatments and genotypes are indicated. NeuT;Apln+/+ control (n = 4), NeuT;Apln/ control (n = 5), NeuT;Apln+/+ sunitinib (n = 4), NeuT;Apln/ sunitinib (n = 5);
***P < 0.001, compared to untreated control NeuT;Apln+/+ mice and §P < 0.05 compared to sunitinib-treated NeuT;Apln+/+ mice; two-way ANOVA. Of note, in NeuT;
Apln+/+ mice, only two tumors could be analyzed after 6 weeks as some mice had to be sacrificed due to the large tumor sizes following ethical guidelines. Thus,
we did not perform any statistical analysis on the 6 weeks time points.
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angiopoietin-2 is additive to reduce angiogenesis and tumor growth,
it may promote even greater hypoxia than monotherapy (Koh et al,
2010; Rigamonti et al, 2014; Scholz et al, 2016). Targeting Apelin
not only reduces growth and angiogenesis in our lung and breast
cancer models, but also, most importantly, it does not result in
increased hypoxia within the tumor microenvironment. Moreover,
blocking Apelin nearly entirely prevents sunitinib-induced metas-
tases. This is of particular importance, because drug-induced
hypoxia is a key factor for drug resistance, metastasis, and meta-
bolic reprogramming of cancer cells (Casanovas et al, 2005;
Mazzone et al, 2009; Loo et al, 2015; Park et al, 2017). Preventing
cancer hypoxia may therefore provide a mechanistic rationale for
combination therapy with chemotherapeutics and radiation therapy,
other anti-angiogenic treatments, perhaps even immune therapy
(Mauceri et al, 1998; Jain, 2005). In summary, we have identified a
druggable pathway that could stratify and protect cancer patients
from resistance to current anti-angiogenic therapies and consequent
metastasis, with the important feature of avoiding increased hypoxia
and thus opening a new avenue for cancer treatment.
Materials and Methods
Mice
Apelin knockout mice (Apln/ or Apln/y) were generated previ-
ously in our laboratories and carry a deletion of the Apelin gene in
the germline (Kuba et al, 2007). These mice were backcrossed for at
least ten generations onto a C57BL/6 background and then crossed
to LSL-KRasG12D mice (Jackson, 2001) to generate LSL-KRasG12D;
Apln/y. p53fl/fl mice have been previously described (Jackson et al,
2005). MMTV-NeuT transgenic mice, which carry the activated c-
Neu oncogene driven by a mouse mammary tumor virus (MMTV)
promoter (Muller et al, 1988), were crossed to C57BL/6 Apln/
mice to generate MMTV-NeuT;Apln/ animals. Tumor onset of
mammary tumors was determined by weekly palpation of the
mammary glands; mice were sacrificed when the tumor size reached
the maximum permitted under ethical guidelines. Anti-angiogenic
treatment with the multimodal receptor tyrosine kinase (RTK) inhi-
bitor sunitinib malate (1611, Biovision, 60 mg/kg body weight per
dose by oral gavage, three times a week) was started only after
cancer onset and followed until the mice were sacrificed. Mice were
maintained in temperature-controlled conditions, and genotypes
were determined by PCR analysis of genomic DNA. In all experi-
ments, mice were randomly distributed between the different groups
and only littermate mice were used as controls. All mice were
maintained according to the ethical animal license protocol comply-
ing with the Austrian and European legislation.
Histology, whole-mount sections, immunohistochemistry, and
immunofluorescence analysis
Tissue samples were fixed in freshly prepared 4% paraformalde-
hyde (PFA) overnight at 4°C and embedded in paraffin after dehy-
dration in ascending concentrations of ethanol. For histological
analysis, 2- to 4-lm-thick paraffin sections were prepared and
stained with hematoxylin and eosin. Slides were evaluated with a
Zeiss Axioskop 2 MOT microscope and scanned with a Pannoramic
250 Flash II Scanner (3D Histech). Tumor burden was evaluated by
a pathologist and also automatically scored by an algorithm
programmed and executed using the Definiens Tissue Studio soft-
ware suite. Histopathologic designations were assigned to prolifera-
tive lesions of the mammary glands in accordance with the
recommendations of the Annapolis Pathology Panel (Cardiff et al,
2000) and the INHAND project (Rudmann et al, 2012). For histolog-
ical analysis of lung tumors, sections from at least two different
longitudinal planes of the lungs were cut and analyzed. Mitotic
counts were performed manually by a pathologist; 10 representative
fields were counted per tumor. The quantification of the number of
dilated vessels per mammary tumor was done by a pathologist; only
vessels with prominent dilated lumina (bigger than 0.25 mm in
length/diameter) in intact viable tumors and inside the tumor
boundaries were enumerated. Numbers of metastatic lung foci were
manually counted by a pathologist; sections from three different
longitudinal planes of the lungs were cut and analyzed. For
immunohistochemistry, the automated Leica Bond III system was
used. Ki67-positive cells and percentages of CD31 positive areas per
tumor were automatically scored by an algorithm programmed and
executed using the Definiens Tissue Studio software suite and visu-
ally controlled by a pathologist in a blinded fashion. For immunoflu-
orescence, sections were deparaffinized in xylene and hydrated in
subsequent dilutions of ethanol (100, 95, 70%), each two times for
5 min. Following antigen retrieval with unmasking solution (1:100
dilution, Vector Labs H3300) in a microwave, sections were cooled
down at room temperature (RT), washed with PBS, blocked with
4% goat serum for 30 min (RT), and stained overnight with primary
antibody at 4°C. The chosen fluorophore-conjugated secondary anti-
body was incubated for 45 min at RT, washed, and mounted in
Vectashield (Vector labs, H-1000). CD31-positive areas were manu-
ally quantified; at least five representative fields were counted per
tumor. To quantify the mural cell coverage of vessels, virtually all
intra-tumoral CD31+ vessels were manually selected and an
◀ Figure 6. Apelin inactivation reduces sunitinib therapy-induced metastasis and stratifies sunitinib therapy responses in patients.A Number of metastatic lung foci in untreated (control) and sunitinib-treated (60 mg/kg, three times a week from tumor initiation) NeuT;Apln+/+ or NeuT;Apln/ mice,
assessed 6 weeks after mammary tumors were size-matched. Data of individual lung sections and means (black bars) are shown. Right panels show representative
H&E images, where black arrows and insets indicate metastatic foci. Scale bars = 1,000 lm (large panels) and 50 lm (insets). *P < 0.05, **P < 0.01; ***P < 0.001;
Kruskal–Wallis test; n = 3 mice per cohort and three sections per lung were analyzed.
B Kaplan–Meier survival plot for distant metastasis-free survival from the KM-plotter database (Gy}orffy et al, 2013) for high and low Apelin (APLN)-expressing groups in
human breast cancer. Patients were split by the median. Affymetrix Apelin ID 222856_at.
C Kaplan–Meier plot for progression-free survival stratifying RCC patients with high and low APELIN serum levels 3–5 months after the start date of sunitinib
treatment. *P = 0.0367; log-rank test.
D Kaplan–Meier plots for progression-free survival in RCC patients stratified into groups of high or low levels of APELIN and VEGF. Cutoff levels were set by the median.
Serum was analyzed 3–5 months after the start date of sunitinib treatment. *P < 0.05, **P < 0.01; log-rank test.
Source data are available online for this figure.
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algorithm, programmed and executed using the Definiens Tissue
Studio software, detected alphaSMA+ (alpha smooth muscle actin)
and CD31+ cells. CA9+ cells were quantified by manual selection of
100–200 peri-vascular intra-tumoral regions and subsequent auto-
matic analysis by an algorithm programmed and executed using the
Definiens Tissue Studio software. Pimonidazole positive hypoxic
foci were manually counted by a pathologist. For immunohisto-
chemistry and immunofluorescence, the primary antibodies used
were as follows: anti-Ki67 (ab16667, Abcam, 1:200), anti-CD31
(DIA310, Dianova, 1:20), anti-alphaSMA (Clone 1A4, Dako, 1:20),
and anti-CA9 (AF2344, R&D Systems, 1:20). For pimonidazole stain-
ing, the HydroxyprobeTM kit (HP1-200Kit, Hydroxyprobe) was used.
Magnetic resonance imaging (MRI)
MRI was performed on a 15.2 T Bruker system (Bruker BioSpec,
Ettlingen, Germany) with a 35-mm quadrature birdcage coil. Mice
were continuously monitored for tumor occurrence by palpation and
MRI. When tumors reached 20–70 mm3, this time point was set as
imaging day 0, and then, each tumor was imaged thereafter at 2, 4,
and 6 weeks. Before imaging, a tail line was inserted for delivery of
contrast agent (30-gauge needle with silicon tubing). All animals were
anesthetized with isoflurane (4% induction, maintenance with
1.5%). During imaging, respiration was monitored and isoflurane
levels were adjusted if breathing was < 20 or > 60 breaths per
minute. For measurement of tumor volume, a multi-slice multi-echo
(MSME) spin-echo sequence was used [repetition time (TR)/echo
time (TE) = 3,000/5.8–81.18 ms, 14 echoes, 117 lm2 in-plane resolu-
tion, 0.5 mm slice thickness, number of experiments [NEX] = 1).
Tumor volume was calculated by multiplying the slice thickness with
the tumor area by an investigator blinded to the treatment group.
Dynamic susceptibility contrast (DSC) perfusion MRI was
collected using fast imaging with steady-state precession (FISP) with
500.6 ms temporal resolution (1 slice; TR/TE = 500/1.7 ms; flip-
angle = 5 degrees; 468 × 468 lm2 in-plane resolution; 1-mm slice
thickness; NEX = 2; 360 repetitions) following tail vein injection of
0.05 ml of 0.25 mol/l gadolinium-based contrast agent (Magnevist,
Berlex). Prior to and following DSC-MRI, a T1-weighted spin-echo
dataset was acquired (0.5 mm thick slices, TR/TE 500/5.8 ms,
117 × 117 lm2 resolution, 2 NEX). DSC data were processed offline
using ImageJ (National Institutes of Health; rsbweb.nih.gov/ij/),
and the DSCoMAN plug-in (Duke University, https://dblab.duhs.d
uke.edu/wysiwyg/downloads/DSCoMAN_1.0.pdf). The analysis
consisted of truncating the first five time points in the DSC-MRI time
series to ensure steady-state magnetization, calculating the pre-
bolus signal intensity (S0) on a pixel-wise basis, converting the trun-
cated DSC-MRI time series to a relaxivity–time curve
(DR2ðtÞ ¼ ð1=TFÞ lnðSðtÞ=S0Þ), SðtÞ) is dynamic signal intensity
curve, and correcting for the gadolinium leakage (K2), as well as
vessel density, as described previously (Boxerman et al, 2006). The
effect of contrast agent leakage (K2) was estimated based on pixels
that exhibited signal enhancement following gadolinium injection
compared to pixels that did not. Necrotic areas seen as hyperintense
on T1-weighted scans were excluded as they lack viable tumor
vasculature. To account for possible small differences in the amount
of contrast agent administered from mouse to mouse, all tumor K2
maps were subsequently corrected for K2 of the muscle (muscle K2
was set to 1).
Embryoid bodies and 3D vascular sprouts
EBs were generated as previously described (Jakobsson et al, 2010).
Briefly, mESCs were trypsinized, depleted of LIF, mixed 1:1 in case
of chimeric EBs and left in low adhesion plates (MS-9096UZ, Sumit-
omo Bakelite Co; day 0). On day five (CCEs) or day eight (Apln GO
and STOP mESCs), the formed EBs were transferred to a polymer-
ized collagen I gel with addition of 30 ng/ml VEGFA164 (Peprotech;
Jakobsson et al, 2010). The medium was changed every day after
sprouting initiation. Apelin (ApelinPyr13, 1,000 nM, BACHEM H-
4568) or DMSO (control) was added, when indicated, after sprout-
ing initiation.
Mammary cancer orthotopic model
E0771 cells were orthotopically injected in C57BL/6J mice as previ-
ously described (Ewens et al, 2005). In brief, cells were harvested for
injection into mice by trypsin digestion for 5 min, washed in Hank’s
balanced salt solution, counted, diluted in this salt solution, and
orthotopically injected into the fat pad of the fourth mammary gland
(2.5 × 105 cells/200 ll/mouse, unless stated otherwise). Treatment
with sunitinib malate (1611, Biovision, 60 mg/kg body weight per
dose by oral gavage, three to five times a week), the Apelin antago-
nist MM54 (057-07, Phoenix Pharmaceuticals, 0.4 mg/kg body
weight per dose by intra-peritoneal injection, three times a week),
axitinib (A-1107, LC Laboratories, 30 mg/kg body weight per dose by
oral gavage, daily), or the anti-VEGFR2 antibody (clone DC101, BioX-
cell, 1 mg by intra-peritoneal injection, twice a week) was started
only after tumors were palpable and followed until the mice were
sacrificed following the ethical guidelines. Mice were randomly
distributed between the different groups. Tumors were measured
using digital calipers; the size of the tumor is expressed as length
(mm) × width (mm) × height (mm) = tumor size (mm3).
Sunitinib-treated RCC cancer patients
Serum samples from renal cell carcinoma (RCC) patients were
collected between 2010 and 2013 3–5 months after sunitinib therapy
at the Department of Urology, Semmelweis University (Budapest,
Hungary). The study protocol was approved based on the ethical
standards prescribed by the Helsinki Declaration of the World Medi-
cal Association and with the permission of the Scientific and
Research Committee of the Hungarian Medical Research Council
(ETT TUKEB 2521-0/2010-1018EKU, 153/PI/010). Samples were
prepared from approximately 10 ml blood collected with BD Vacu-
tainer Serum Separator tube (#367953). Samples were allowed to
clot for 45 min at room temperature before being centrifuged at
2,650 g for 15 min, aliquoted, and stored at 80°C until use. Cutoff
levels for high and low APELIN or VEGF levels were set by the
median. Kaplan–Meier curves for progression-free survival were
evaluated for all patients, and the log-rank test was used to establish
the significance of the difference. Multivariate analysis of the clini-
cal parameters was performed using the Cox regression model.
Statistical analyses were performed using the PASW Statistics 18.0
package (Predictive Analytics Software, SPSS Inc., Chicago, IL,
USA), the IBM SPSS Statistics 23.0 package (IBM Corp., Armonk,
NY, USA), and GraphPad Prism 6.0 (GraphPad Inc., San Diego, CA,
USA).
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Induction of lung cancer
Intratracheal administration of adenoviruses expressing Cre was
used to specifically induce K-RasG12D expression and p53 deletion in
pneumocytes. Administration of AdCre viruses was performed in 8-
to 12-week-old mice as previously reported (DuPage et al, 2009). In
brief, experimental animals were anesthetized with Ketasol: Xylasol
and placed on a heated pad. An AdCre-CaCl2 precipitate was
produced by mixing 60 ll MEM, 2.5 ll AdCre (4 × 1010 pfu/ml;
University of Iowa, Gene Transfer Vector Core Iowa, USA) and
0.6 ll CaCl2 (1 M) for each mouse and incubated for 20 min at
room temperature (21–22°C).
Primary cells and cell lines
E0771 breast adenocarcinoma cells were purchased from ATCC and
maintained as a monolayer in RPM1 1640 supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, penicillin/streptomycin
(100 U Pen/ml; 0.1 mg Strep/ml), and 10 mM HEPES buffer.
Primary human umbilical vein endothelial cells (HUVECs) were
purchased from Life Technologies and maintained in Medium 200
(Life Technologies) supplemented with Low Serum Growth Supple-
ment as specified by the supplier (LSGS, Life Technologies). Cells
were kept at low passage and tested for mycoplasma regularly. All
cells were mycoplasma negative.
Mouse embryonic stem cells
Apelin STOP (GFP+) and Apelin GO (mCherry+;Cre+) mouse
embryonic stem cells (mESCs) as well as CCE mESCs were cultured
in DMEM with 15% fetal calf serum (Invitrogen), penicillin/strepto-
mycin (100 U Pen/ml; 0.1 mg Strep/ml), L-glutamine (2 mM), non-
essential amino acids, 1 mM sodium pyruvate, 50 mM b-mercap-
toethanol, and leukemia inhibitory factor (LIF). All cells were main-
tained at 37°C and 5% CO2 conditions.
Plasmids and retroviral infections
Apelin and Apelin receptor shRNAs were cloned into a GMPNIL
retroviral vector (SSCV-GFP-miRE-PGK-Neomycin-IRES-Luciferase
2). PlatE cells were cultured at 37°C and 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and transfected using the calcium phosphate co-
precipitation method. Selection of E0771 was done with 400 lg/
ml of neomycin. Haploid murine ESCs carrying a Tol2 gene-trap
vector between exons 1 and 2 of the Apelin gene (named Apln
STOP mESCs) were generated in-house by Haplobank. Reversion
of the splice acceptor element, to genetically “repair” the muta-
tion (named Apln GO), was done by infection with a retroviral
plasmid encoding for Cre recombinase as well as mCherry
(MSCV-mCherry-IRES-Cre).
Vascular permeability assay
Lysinated labeled dextran (70 kDa; Invitrogen, D1818, 1.25 mg in
100 ll ddH2O) was intravenously injected into the tail vein of each
tumor-bearing mouse. Fifteen minutes post-injection, mice were
sacrificed and tumors were harvested, followed by overnight
fixation in 4% PFA. Whole-mount immunostaining of tumor
samples was performed with anti-CD31 antibodies (DIA310,
Dianova) followed by a goat Alexa 633 secondary antibody. Positive
signals were examined by confocal microscopy and the numbers of
vessels with extravasated dextran were quantified and corrected for
differences in vessel densities.
Pimonidazole hypoxia assay
Pimonidazole (HydroxyprobeTM kit, HP1-200Kit, hydroxyprobe,
12 mg/ml in PBS) was intravenously injected at 60 mg/kg into the
tail vein of each tumor-bearing mouse. Mice were sacrificed
45 min post-injection and tumors were harvested, followed by
overnight fixation in 4% PFA. Immunohistochemical staining of
tumor samples was performed according to the manufacturer’s
instructions.
Flow cytometry
Flow cytometry sorting of endothelial cells from tumors was
performed by dissociating tumors with 2 mg/ml collagenase IV
(LS004186, Worthington) and 0.2 mg/ml deoxyribonuclease I
(LS002138, Worthington) in RPMI medium for 45 min at 37°C. The
collagenase/Dnase solution was replaced with 10 ml cold FACS
buffer (PBS, 2% fetal bovine serum), and the dissociated cells were
passed through a 70-lm cell strainer and then washed with 10 ml
cold FACS buffer. The cells were stained with APC-conjugated anti-
mouse CD31 antibody (17-0311, eBioscience, 1:100), PE-conjugated
anti-mouse CD105 antibody (120408, Biolegend, 1:100), PE-Cy7-
conjugated anti-mouse CD45 (103114, Biolegend, 1:400), as well as
including an anti-mouse CD16/CD32 Fc block (553142, BD Bios-
ciences, 1:100) and DAPI (D1306, Thermo Fisher Scientific, 1:500
from a 5 mg/ml stock) all diluted in FACS buffer and incubated for
20 min at 4°C. Endothelial cells were isolated by sorting for DAPI,
CD45, CD31+, and CD105+ cells on a FACS Aria III cytometer. All
data were analyzed with FlowJo v10.0.8r1.
For analysis of infiltrating immune cells, single-cell suspensions
from tumors were prepared as described above. The staining was
split into two panels, panel one was comprised of FITC-conjugated
anti-mouse CD45 antibody (103107, eBioscience, 1:500), PerCP-
Cy5.5-conjugated anti-mouse Cd11b antibody (101228, BioLegend,
1:200), PE-Cy7-conjugated anti-mouse Thy1.2 antibody (B105326,
Biolegend, 1:100), BV510-conjugated anti-mouse Ly6G-antibody
(127633, BioLegend, 1:100), BV711-conjugated anti-mouse NK1.1
antibody (108745, BioLegend, 1:100), BV-570-conjugated anti-
mouse CD4 antibody (B100542, BioLegend, 1:250), EF450-conju-
gated anti-mouse CD8 antibody (48-0081-80, eBiolegend, 1:300),
eFlour780-conjugated fixable viability dye (65-0865-14, eBio-
science, 1:1,000) as well as including an anti-mouse CD16/CD32
Fc block (553142, BD Biosciences, 1:100). Panel 2 was comprised
of AF488-conjugated anti-mouse B220/CD45R antibody (103225,
BioLegend, 1:100), PerCP-Cy5.5-conjugated anti-mouse Cd11b anti-
body (101228, BioLegend, 1:200), PE-Cy7-conjugated anti-mouse
CD45 antibody (552848, BD Biosciences, 1:500), BV510-conjugated
anti-mouse Ly6G-antibody (127633, BioLegend, 1:100), BV785-
conjugated anti-mouse Ly6C antibody (128041, BioLegend, 1:100),
APC-conjugated anti-mouse PDCA1 antibody (17-3171-80, Thermo
Fisher Scientific, 1:100), eFlour780-conjugated fixable viability dye
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(65-0865-14, eBioscience, 1:1,000) as well as an anti-mouse CD16/
CD32 Fc block (553142, BD Biosciences, 1:100), all diluted in
FACS buffer and incubated for 30 min at 4°C. Cells were acquired
on a BD LSR Fortessa. All data were analyzed with FlowJo
v10.0.8r1.
Flow cytometry analysis and sorting of endothelial cells in
vessel sprouts were performed as described (Jakobsson et al,
2010). In brief, embryoid bodies in collagen were dissociated by
treatment with 2.5 mg/ml collagenase A (10103578001, Roche) in
ESC media without LIF, for 45 min at 37°C. The collagenase A
solution was replaced with 10 ml cold FACS buffer (PBS, 2% fetal
bovine serum and 25 mM HEPES), and the EBs were passed
through a 70-lm cell strainer and then washed with 10 ml cold
FACS buffer. The cells were stained with APC-conjugated anti-
CD31 antibodies (17-0311, eBioscience, 1:100) including an anti-
mouse CD16/CD32 Fc block (553142, BD Biosciences, 1:100), all
diluted in FACS buffer and incubated for 20 min at 4°C. FACS was
performed using a FACS Aria III cytometer. All data were analyzed
with FlowJo v10.0.8r1.
Gene expression analysis
Total RNA of tumors, isolated mammary epithelial cells, and tumor
endothelial cells were prepared using the RNeasy Mini Kit (Qiagen),
according to the manufacturer’s instructions. cDNA synthesis was
performed using the iScript cDNA synthesis kit (Bio-Rad). RT-qPCR
analyses were carried out according to the manufacturer’s instruc-
tions. Values were normalized by the expression of housekeeping
genes as previously described (Uribesalgo et al, 2011).
Short hairpin RNA and primer sequences
The 22mer sequences are as follows:
Apln shRNA (MirE.2038), 50-TAAGTGAATATCGAGCTTCTGT-30;
Aplnr shRNA (MirE.2029), 50-TTGAAAGATACAGAGCTCCTGG-30.
Primer sequences for RT-qPCR analysis are as follows:
Apln forward primer: 50-GCTCTGGCTCTCCTTGACTG-30;
Apln reverse primer: 50-CTCGAAGTTCTGGGCTTCAC-30;
Aplnr forward primer 50-GAGTTTGACTGGCCTTTTGG-30;
Aplnr reverse primer 50-GGTATCGGTCAAAGCTGAGG-30;
PUM1 forward primer 50-TGTGGTCCAGAAGATGATCG-30
PUM1 reverse primer 50-GGATGTGCTTGCCATAGGTG-30;
bActin forward primer 50-CGGTTCCGATGCCCTGAGGCTCTT-30;
bActin reverse primer 50-CGTCACACTTCATGATGGAATTGA-30.
RNA-Seq data analysis
Full RNA was isolated from sorted tumor endothelial cells (TEC)
and prepared as described by Picelli et al (2014), with the following
changes: Cells were sorted in 4 ll lysis buffer, to which oligo-dT and
dNTP were added. For Tagmentation, in-house produced Tn5 was
used. PolyA-mRNA was isolated from endothelial cells FACS-sorted
from sprouting vessels (ES) in the presence or absence of Apelin.
Both generated libraries were sequenced by 50-bp single-end Illu-
mina mRNA sequencing. Reads were aligned using star v2.5.0a (ES)
or v2.6c (TEC) in 2-pass mode, TPM estimation was performed with
RSEM v1.2.25 (ES) or v1.2.28 (TEC), aligned reads were counted with
HTSeq v0.6.1p1 (ES) or featurecounts subread v1.6.2 (TEC), and
differential expression analysis was performed with DESeq2 v1.10.1
(ES) or v1.18.1 (TEC). Gene sets with significant enrichment were
selected based on a false discovery rate (FDR) q value cutoff of 5%.
Heatmaps show scaled log2 gene expression values (log2(TPM + 1))
for differentially expressed genes (Padj < 0.05 and absLog2
(Foldchange) > 1, DESeq2 v1.10.1 or v1.18.1). Differentially
expressed gene lists were analyzed for the enrichment of canonical
pathways using IPA (ingenuity pathways analysis; Ingenuity Systems,
http://www.ingenuity.com) where the effect directionality is esti-
mated based on the provided logarithmic fold change values for the
compared groups (DESeq2). GO analysis was performed with the
online DAVID software.
ELISA assays
Quantikine VEGF ELISA (DVE00, R&D Systems) and Apelin-36
ELISA (EKE-057-15, Phoenix Pharmaceuticals) kits were used.
Sample preparation, standard curve generation, and measurement
of samples in duplicates were performed according to the guidelines
of the manufacturer.
Human database analysis
To analyze the prognostic value of Apelin in human cancer, we
performed unbiased meta-analysis of publicly available cancer
microarray datasets with clinical annotation. For breast cancer,
patient cohorts of 664 samples (distant metastasis-free survival)
and 1,764 samples (relapse-free survival) were analyzed using the
online survival analysis tool Kaplan–Meier Plotter (Gy}orffy et al,
2010; probe 222856_at); the data set GSE6532-GPL570 from the
PrognoScan database was also analyzed (Mizuno et al, 2009). For
lung cancer, a patient cohort of 1,145 samples from the Kaplan–
Meier Plotter was analyzed (probe 222856_at) (Gyo¨rffy et al,
2013).
Statistics
Values are given as means  standard error of the mean (SEM)
unless otherwise stated. For tumor experiments, only mice that
developed tumors were included in the analysis. Mice were allo-
cated to experimental groups on the basis of their genotype and
randomized within the given group. Sample sizes were typically
between n = 3–6 samples per group and at least n = 7–8 for
survival curves. For animal studies, the investigator was typically
blinded toward the genotype, but not the treatment group. Single
comparisons were analyzed by two-tailed Student’s t-test or Mann–
Whitney test in non-normally distributed data; multiple compar-
isons were analyzed by one-way ANOVA, two-way ANOVA, or
Kruskal–Wallis test in non-normally distributed data followed by
post hoc tests for multiple comparisons. Normality was tested using
the D’Agostino–Pearson test for n > 7; otherwise, Shapiro–Wilk was
used. F test and Brown–Forsythe test were used to assess the equal-
ity of variances. For the Kaplan–Meier survival analysis, a log-rank
test was performed. P-values are indicated in each figure legend.
P < 0.05 was considered to indicate statistical significance. All exact
P-values are listed in the Appendix Table S1. Statistical analysis was
performed using GraphPad Prism (GraphPad Software, San Diego,
CA, USA).
16 of 19 EMBO Molecular Medicine 11: e9266 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Iris Uribesalgo et al
Data availability
The datasets produced in this study are available in the following
databases:
• RNA-Seq: Gene Expression Omnibus GSE100293 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100293)
Expanded View for this article is available online.
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